Editas Medicine's Return On Capital Employed Insights
Portfolio Pulse from Benzinga Insights
Editas Medicine (NASDAQ: EDIT) reported Q1 sales of $9.85 million and an overall loss of $49.04 million. The company's return on capital employed (ROCE) was -0.15%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.71, beating analyst predictions of $-0.78.
May 19, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Editas Medicine's Q1 sales were $9.85 million with a loss of $49.04 million. The company's ROCE of -0.15% indicates inefficient capital allocation. Q1 EPS was $-0.71, better than analyst predictions.
Editas Medicine's Q1 sales and EPS beat analyst predictions, which could be seen as a positive sign. However, the company's negative ROCE of -0.15% suggests inefficient capital allocation, which could negatively impact the stock price. The overall impact on the stock price is neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100